<?xml version="1.0" encoding="UTF-8"?>
<p id="para0016">On January 13, 2020, the U.S. National Institutes of Health (NIH) finalized the sequence for a potential mRNA vaccine, mRNA-1273 
 <xref rid="bib0073" ref-type="bibr">[73]</xref>. mRNA-1273 is a vaccine that encodes for a prefusion stabilized form of the S protein of SARS-CoV-2. On March 16, 2020, the NIH announced that the first participant in its Phase I study for mRNA-1273 was dosed. The mRNA platform offers significant advantages in terms of speed and efficiency from the perspectives of basic science, manufacturing and clinical development.
</p>
